{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:29:10Z","timestamp":1762867750975},"reference-count":51,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.2217\/fmb-2018-0303","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T12:28:07Z","timestamp":1552307287000},"page":"461-475","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["ZTI-01 (Fosfomycin for Injection) in the Treatment of Hospitalized Patients With Complicated Urinary Tract Infections"],"prefix":"10.1080","volume":"14","author":[{"given":"Rodrigo M","family":"Burgos","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice,College of Pharmacy,University of Illinois at Chicago,\rChicago,\rIL,\r60612,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A","family":"Rodvold","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice,College of Pharmacy,University of Illinois at Chicago,\rChicago,\rIL,\r60612,\rUSA"},{"name":"Department of Medicine,College of Medicine,University of Illinois at Chicago, \rChicago,IL,60612,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.166.3901.122"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-15"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2017.1379897"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902967624"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70325-1"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.12.005"},{"key":"e_1_3_3_9_1","unstructured":"Allergan USA Inc . Highlights of prescribing information: Monurol\u00ae (fosfomycin tromethamine) granules for oral solution ( 2018 ). www.allergan.com\/assets\/pdf\/monurol_pi ."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz181"},{"key":"e_1_3_3_11_1","volume-title":"ID Week 2018","author":"Kaye KS","year":"2018","unstructured":"Kaye KS , RiceLB , StusVet al. Clinical cure in secondary efficacy populations in patients with complicated urinary tract infection treated with ZTI-01 (fosfomycin for injection): findings from the ZEUS Trial . Presented at : ID Week 2018 . San Francisco, CA, USA , 3\u20137 October 2018 ."},{"key":"e_1_3_3_12_1","unstructured":"Nabriva Therapeutics US Inc . Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO\u2122 to Treat Complicated Urinary Tract Infections ( 2018 ). https:\/\/investors.nabriva.com\/news-releases\/news-release-details\/nabriva-therapeutics-completes-submission-new-drug-application ."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.06.013"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2014.12.002"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw281"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020251"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.11.2217"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201710030"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0438"},{"key":"e_1_3_3_22_1","unstructured":"Achaogen Inc . Highlights of prescribing information: Zendri\u2122 (plazomicin) injection ( 2018 ). www.zemdri.com\/assets\/pdf\/Prescribing-Information.pdf ."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.166.3901.123"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-009-0833-2"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.08.010"},{"key":"e_1_3_3_26_1","volume-title":"ASM Microbe 2017","author":"Shortridge D","year":"2017","unstructured":"Shortridge D , FlammRK , RhombergPRet al. Fosfomycin in vitro activity against bacteria with various mechanisms of resistance to other antibacterials from US hospitals . Presented at : ASM Microbe 2017 . New Orleans, LA, USA , 3\u20136 June 2017 ."},{"key":"e_1_3_3_27_1","volume-title":"ASM Microbe 2017","author":"Clancy CJ","year":"2017","unstructured":"Clancy CJ , Hong NguyenM , HaoBet al. ZTI-01 (Fosfomycin (FOS) for injection) activity against carbapenem-resistant and ceftazidime- avibactam resistant Enterobacteriaceae (CRE) clinical isolates with diverse resistance mechanisms . Presented at : ASM Microbe 2017 . New Orleans, LA, USA , 3\u20136 June 2017 ."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1974.tb43277.x"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.062653-0"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8912039"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.920"},{"key":"e_1_3_3_32_1","volume-title":"ASM Microbe 2017","author":"Rhomberg PR","year":"2017","unstructured":"Rhomberg PR , LindleyJM , SaderHSet al. Evaluation of the antimicrobial activity of fosfomycin when combined with selected antimicrobial agents and tested against bacterial isolates using checkerboard methods . Presented at : ASM Microbe 2017 . New Orleans, LA, USA , 3\u20136 June 2017 ."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00775-17"},{"key":"e_1_3_3_34_1","volume-title":"American Society of Microbiology Microbe 2017","author":"Trang M","year":"2017","unstructured":"Trang M , ForrestA , BhavnaniSM , Ellis-GrosseEJ , AmbrosePG , RubinoCM . Population pharmacokinetic analysis of ZTI-01 (fosfomycin for injection) using Phase I data for ZTI-01 and evaluation of a Phase II\/III PK sampling strategy (poster Saturday 151) . Presented at : American Society of Microbiology Microbe 2017 . New Orleans, LA, USA , 1\u20135 June 2017 ."},{"key":"e_1_3_3_35_1","volume-title":"IDWeek 2017","author":"Trang M","year":"2017","unstructured":"Trang M , Ellis-GrosseEJ , EckburgPB , SkarinskyD , BhavnaniSM , RubinoCM . Population pharmacokinetic (PPK) analysis of ZTI-01 (fosfomycin for injection) using data from healthy subjects and patients with complicated urinary tract infections (cUTI) (poster 1848) . Presented at : IDWeek 2017 . San Diego, CA, USA , 4\u20138 October 2017 ."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04955-14"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-16"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02627-17"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00476-17"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00752-15"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01682-18"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01815-17"},{"key":"e_1_3_3_43_1","volume-title":"American Society of Microbiology Microbe 2017","author":"Bhavnani SM","year":"2017","unstructured":"Bhavnani SM , TrangM , RubinoCM , LepakAJ , AndesDR , FlammRK , SweeneyK , Ellis-GrosseEJ , AmbrosePG . Pharmacokinetics-pharmacodynamics target attainment to support ZTI-01 (fosfomycin for injection) dose selection for patients with complicated urinary tract infections (cUTI) (poster Saturday 152) . Presented at : American Society of Microbiology Microbe 2017 . New Orleans, LA, USA , 1\u20135 June 2017 ."},{"key":"e_1_3_3_44_1","first-page":"1392","volume-title":"Kucers\u2019 The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs (Volume 1)","author":"Frimodt-M\u2298ller N","year":"2017","unstructured":"Frimodt-M\u2298ller N . Fosfomycin . In : Kucers\u2019 The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs (Volume 1) . GraysonML , CosgroveSE , CroweSet al.( Eds ) . CRC Press , Boca Raton, FL, USA , 1392 \u2013 1406 ( 2017 )."},{"key":"e_1_3_3_45_1","volume-title":"ID Week 2017","author":"Ellis-Grosse EJ","year":"2017","unstructured":"Ellis-Grosse EJ , SkarinksyD , DasAet al. Phenotypic antibiotic resistance in ZEUS: a multi-center, randomized, double-blind Phase II\/III study of ZTI-01 versus piperacillin-tazobactam (P-T) in the treatment of patients with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP) . Presented at : ID Week 2017 . San Diego, CA, USA , 4\u20138 October 2017 ."},{"key":"e_1_3_3_46_1","volume-title":"ID Week 2017","author":"Rice LB","year":"2017","unstructured":"Rice LB , KayeKS , DaneAet al. Safety results from the ZEUS study: multi-center, randomized, double-blind Phase II\/III study in hospitalized adults with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP) who received intravenous fosfomycin (ZTI-01) . Presented at : ID Week 2017 . San Diego, CA, USA , 4\u20138 October 2017 ."},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.09.002"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-15"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0092-8"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp170123"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2017.09.019"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky283"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr466"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2018-0303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:40:45Z","timestamp":1719124845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2018-0303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.2217\/fmb-2018-0303"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2018-0303","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}